Advances in Oncology, 2024: Advances, cartea 4-1
Editat de Leonidas C. Plataniasen Limba Engleză Hardback – apr 2024
Din seria Advances
- 5%
Preț: 720.33 lei - 5%
Preț: 952.85 lei - 5%
Preț: 1234.55 lei - 5%
Preț: 932.16 lei - 5%
Preț: 1232.56 lei - 5%
Preț: 1164.83 lei - 5%
Preț: 1163.45 lei - 5%
Preț: 1233.31 lei - 5%
Preț: 1274.99 lei - 5%
Preț: 1127.64 lei - 25%
Preț: 737.37 lei - 25%
Preț: 670.71 lei - 30%
Preț: 986.68 lei - 5%
Preț: 822.83 lei - 30%
Preț: 977.14 lei - 25%
Preț: 666.98 lei - 25%
Preț: 590.62 lei - 25%
Preț: 709.57 lei - 25%
Preț: 735.94 lei - 25%
Preț: 860.88 lei - 25%
Preț: 807.44 lei - 25%
Preț: 791.35 lei - 25%
Preț: 809.13 lei - 25%
Preț: 871.01 lei - 30%
Preț: 872.02 lei - 5%
Preț: 493.69 lei - 30%
Preț: 596.38 lei - 25%
Preț: 975.82 lei - 25%
Preț: 671.31 lei - 25%
Preț: 808.34 lei - 32%
Preț: 850.23 lei - 30%
Preț: 858.45 lei - 5%
Preț: 855.72 lei - 25%
Preț: 689.09 lei - 25%
Preț: 800.14 lei - 25%
Preț: 908.34 lei - 5%
Preț: 907.78 lei - 5%
Preț: 910.14 lei - 25%
Preț: 594.42 lei - 5%
Preț: 854.93 lei - 30%
Preț: 856.93 lei - 25%
Preț: 885.64 lei - 33%
Preț: 854.96 lei - 25%
Preț: 836.55 lei - 5%
Preț: 907.68 lei - 5%
Preț: 492.96 lei - 5%
Preț: 908.66 lei - 27%
Preț: 594.93 lei - 5%
Preț: 1317.29 lei
Preț: 984.69 lei
Preț vechi: 1306.55 lei
-25% Nou
Puncte Express: 1477
Preț estimativ în valută:
174.25€ • 203.20$ • 152.99£
174.25€ • 203.20$ • 152.99£
Carte tipărită la comandă
Livrare economică 09-23 ianuarie 26
Preluare comenzi: 021 569.72.76
Specificații
Cuprins
1. Contemporary Management of Dermatofibrosarcoma Protuberans
2. Management of Locoregional Melanoma
3. Current Management of Intraductal Papillary Mucinous Neoplasms
4. Perioperative Strategies in Non-Small Cell Lung Cancer: Immunotherapy and Targeted Therapy
5. Optimal Front-Line Therapy for Non[1]Oncogene-Driven Non-Small Cell Lung Cancer
6. Beyond First-Line Epidermal Growth Factor Receptor (EGFR)-Tyrosine Kinase Inhibitors (TKI): Approach to Resistance
7. Antibody-Drug Conjugates for the Treatment of Gynecologic Cancer: A Review of the Current Evidence and Clinical Application
8. Surgery for Recurrent Ovarian Cancer
9. Big Data in Pediatric Oncology: Hope, Hype, Reality
10. Imipridones and Dopamine Receptor Antagonism in the Therapeutic Management of Gliomas
11. Diagnostic and Theranostic Opportunities in Neuro-Oncology
12. Updates on Revised Diagnostic Criteria and Targeted Therapies for Neurofibromatosis
13. Management of Relapsed Refractory Large B[1]Cell Non-Hodgkin Lymphoma: Chimeric Antigen Receptor T-Cell Therapy versus Autologous Stem Cell Transplantation
14. T-cell Acute Lymphoblastic Leukemia: Novel Therapies Worth Watching
15. Prognostic Role and Clinical Utility of Measurable Residual Disease in Acute Myeloid Leukemia
16. Role of Circulating Tumor DNA for Monitoring of Recurrence and Treatment Response in Urothelial Cancer
17. Intensification of Androgen Deprivation Therapy in Metastatic Hormone-sensitive Prostate Cancer: 18. Patient Selection and Overview of Doublet and Triplet Therapy Data
19. Adjuvant Therapy for Muscle-Invasive Urothelial Cancer: Current Evidence and Future Directions
20. Defining the Role of Neoadjuvant Therapy for Gastroesophageal Cancers
21. Current and Emerging Therapeutic Options for Human Epidermal Growth Factor Receptor 2-Expressing Gastroesophageal Cancers
22. Contemporary Systemic Therapy Approaches for Unresectable Hepatocellular Carcinoma
23. Multidisciplinary Care and Multimodal Treatment Approaches for Unresectable Hepatocellular Carcinoma
2. Management of Locoregional Melanoma
3. Current Management of Intraductal Papillary Mucinous Neoplasms
4. Perioperative Strategies in Non-Small Cell Lung Cancer: Immunotherapy and Targeted Therapy
5. Optimal Front-Line Therapy for Non[1]Oncogene-Driven Non-Small Cell Lung Cancer
6. Beyond First-Line Epidermal Growth Factor Receptor (EGFR)-Tyrosine Kinase Inhibitors (TKI): Approach to Resistance
7. Antibody-Drug Conjugates for the Treatment of Gynecologic Cancer: A Review of the Current Evidence and Clinical Application
8. Surgery for Recurrent Ovarian Cancer
9. Big Data in Pediatric Oncology: Hope, Hype, Reality
10. Imipridones and Dopamine Receptor Antagonism in the Therapeutic Management of Gliomas
11. Diagnostic and Theranostic Opportunities in Neuro-Oncology
12. Updates on Revised Diagnostic Criteria and Targeted Therapies for Neurofibromatosis
13. Management of Relapsed Refractory Large B[1]Cell Non-Hodgkin Lymphoma: Chimeric Antigen Receptor T-Cell Therapy versus Autologous Stem Cell Transplantation
14. T-cell Acute Lymphoblastic Leukemia: Novel Therapies Worth Watching
15. Prognostic Role and Clinical Utility of Measurable Residual Disease in Acute Myeloid Leukemia
16. Role of Circulating Tumor DNA for Monitoring of Recurrence and Treatment Response in Urothelial Cancer
17. Intensification of Androgen Deprivation Therapy in Metastatic Hormone-sensitive Prostate Cancer: 18. Patient Selection and Overview of Doublet and Triplet Therapy Data
19. Adjuvant Therapy for Muscle-Invasive Urothelial Cancer: Current Evidence and Future Directions
20. Defining the Role of Neoadjuvant Therapy for Gastroesophageal Cancers
21. Current and Emerging Therapeutic Options for Human Epidermal Growth Factor Receptor 2-Expressing Gastroesophageal Cancers
22. Contemporary Systemic Therapy Approaches for Unresectable Hepatocellular Carcinoma
23. Multidisciplinary Care and Multimodal Treatment Approaches for Unresectable Hepatocellular Carcinoma